Status | Study |
Recruiting |
Study Name: Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI) Condition: Primary Immune Deficiency Disorder Date: 2013-06-19 Interventions: Other: Immunoglobulin Therapy |
Active, not recruiting |
Study Name: Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases Condition: Primary Immune Deficiency Disorders Common Variable Immunodeficiency Date: 2013-06-14 Interventions: Biological: Subgam Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg |
Active, not recruiting |
Study Name: Investigation of Immune Disorders and Deficiencies Condition: Primary Immune Deficiencies Autoimmune Diseases Inflammato Date: 2013-05-06 |
Recruiting |
Study Name: Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Condition: Severe Combined Immunodeficiency (SCID) Immunodeficiency With Predominant T-cell Defect, Uns Date: 2013-04-26 Interventions: Biological: CD3/CD19 negative allogeneic hematopoietic stem cells Negative selection for CD3/CD19 will b |
Recruiting |
Study Name: Immune Disorder HSCT Protocol Condition: Immune Deficiency Disorders Severe Combined Immunodeficiency Date: 2013-03-19 Interventions: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan Between days - |
Recruiting |
Study Name: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies Condition: SCID Omenn's Syndrome Reticular Dysgenesis Date: 2012-07-25 Interventions: Drug: Alemtuzumab 0.3 mg 0.3 m |
Terminated |
Study Name: "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency Condition: Common Variable Immunodeficiency Date: 2011-12-08 Interventions: Biological: PPS POLYSACCHARIDE |
Completed |
Study Name: A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Condition: Primary Immune Deficiency Disorders Common Variable Immunodeficiency Date: 2011-01-27 Interventions: Biological: Gammaplex GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intraveno |
Completed |
Study Name: Lymphocyte Immunophenotyping in Common Variable Immunodeficiency Condition: Common Variable Immunodeficiency Granulomatous Disease Date: 2010-09-06 |
Recruiting |
Study Name: Natural History of Bronchiectasis Condition: Bronchiectasis Cystic Fibrosis Autoimmune Disease Date: 2009-07-21 |